Send Message
View as an RSS Feed
  • President Obama is likely to approve a GOP proposal to suspend the debt ceiling until May 19, which has the backing of Senate Majority Leader Harry Reid as well. The House is due to vote on the measure today, with the bill also requiring both chambers to pass budgets by April 15; if they don't members' salaries would be withheld.  [View news story]
    See its easy fellow members of Congress, the public is all consumed with Michelle's hair and fashion so nobody is even paying attention. Surely in May people will be too busy planning vacations and checking out the Spring fashion so we can do it again then as well. For those that are paying attention we will say our paychecks will be withheld but we can just stuff a bill to override that pledge in approval or rejection of the Keystone Pipeline. Party on!
    Jan 23, 2013. 07:34 AM | 1 Like Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout  [View article]
    My wife works in a pharmacy so I have been asking her if she has ordered Vascepa yet. She stated they would order once a prescription is written. It becomes a sale once the pharmacy orders it.
    Jan 21, 2013. 11:30 AM | 1 Like Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout  [View article]
    Adam, shouldn't you get back to writing more of your hack-job articles rather than trolling comment sections? Seems as though there are people in your inner circle that could really use some money to repay money stolen from honest people. Just maybe if you pen a truly honest piece based on an educated opinion supported by facts you could save your family boat. Your a literary giant, how does the old saying go about apples not falling far from trees?
    Jan 18, 2013. 02:41 PM | Likes Like |Link to Comment
  • Cramer's Lightning Round - MAKO Surgical Is A Much-Hyped Stock (1/3/12)  [View article]
    I have found that if I do just the opposite of what he recommends after a 48 hour wait I do just fine.
    Jan 4, 2013. 09:10 AM | 3 Likes Like |Link to Comment
  • The haggling to avert a fiscal cliff brings more movement, with President Obama offering to limit tax increases to those earning over $400K - up from his long-held desire of $250K but well below John Boehner's proposal of $1M. The latter's aides say the offer represents "a step in the right direction" but is too heavy on the tax revenues and too light on the spending cuts.  [View news story]
    I thought utility minimum bills whether you occupy the home year round or not, property taxes, annual vehicle property, registration, and fuel taxes covered the concept of the more you own the more you pay fairly adequately; no?
    Dec 18, 2012. 07:52 AM | 1 Like Like |Link to Comment
  • Amarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier 
    Just what we needed...good news...now the stock will head for the $8's today for certain.
    Dec 11, 2012. 08:12 AM | Likes Like
  • Amarin - Catch And Release  [View article]
    "Amarin is preparing to market Vascepa without partnering, which will be expensive and lack the synergy of being marketed by people experienced in and simultaneously marketing cardiovascular drugs."

    "It will take time to build a sales force, let alone an effective sales force"

    Joe stated 250 offers were going out last Friday out of over 2500 applicants. All offers are going to people with 3-5 years of CV experience. AMRN has been in the process of selecting a sales force over the last several months.

    Using VVUS' (also disgruntled long) online pharmacy marketing results are a detriment to your argument that Vascepa will have a slow launch. From what I have read and listened to in the conference calls leads me to believe that AMRN management has been taking the steps for a seamless launch with numbers that will surprise the naysayers.
    Dec 10, 2012. 02:27 PM | 2 Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout  [View article]
    He lost $100 of daddy's money. Really not worth doing research for that amount of money when it comes so easy
    Dec 7, 2012. 03:56 PM | Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout  [View article]
    I see a sales force as adding more value to the company. Joe stated offers are going out today for 250 reps out of 2500 applicants that have established relationships with CV physicians for at least the last 3 years covering 30,000 physicians. Stated AMRN reps will only be pushing one product versus multiple products. He stated Vascepa has gained coverage in almost every insurance program and they hope to have coverage in every major program prior to launch in late January. He also stated multiple times that discussions with big pharm are still ongoing. The management team has been building a great deal of value through patents and suppliers as well as taking steps to make Vascepa a ready-to-prescribe drug.
    Dec 7, 2012. 11:53 AM | 1 Like Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout  [View article]
    I take it you did not listen to the conference call. If you did you would not say management failed. Exactly what did they fail at?

    Why listen to conference calls when that ring leader has all you clowns in his circus. Get this, AF writes articles for page views, that is how he makes a living. He writes the opposite of what the facts point towards as people want to read ideas contrary to their opinions derived from their own DD. He has been right about nothing.
    Dec 7, 2012. 11:33 AM | 1 Like Like |Link to Comment
  • Discussing Amarin's Vascepa And GlaxoSmithKline's Lovaza With Omthera Pharma  [View article]
    Shocker, one man claims his company's product is better than his competitor's.

    I agree with Steve above. When making points about why your company is better than those you are competing against, stick with hard facts. Reiterating a point he tried to make weeks ago complaining about his competitor's choice in placebo makes me suspect of the rest of the information he provides.
    Dec 4, 2012. 11:18 AM | 3 Likes Like |Link to Comment
  • 2 Stocks To Buy, 2 Stocks To Sell; What's Next For The Market  [View article]
    Amarin received notice of allowance on their ninth patent last week. Advising a short without researching the primary catalyst is dangerous to those whom take you seriously. DO YOUR OWN DD AS THIS PERSON HAS DONE VERY LITTLE.
    Nov 26, 2012. 07:34 AM | 3 Likes Like |Link to Comment
  • Let's Watch Amarin Get Crushed By Wall Street  [View article]
    The cost to defend against generics...say $100 million over 5 years? That's around $0.50 per share. NCE is not what is holding this deal up. Amarin has hit the powerball lottery and wants the lump sum payout. To sell at anything less than $30 would be a huge disappointment. Problem is the CEO of the buying company has to explain to shareholders why they paid $30 for a stock trading at $11. My guess is companies in the running are buying out the weak hands daily and prices will shoot up greatly on the next catalyst, that being Marine results, not NCE. Announcement for buyout deal to follow IMO.
    Oct 12, 2012. 05:47 PM | 1 Like Like |Link to Comment
  • Amarin NCE Decision Delayed Again: What The 8-K Really Tells Us  [View article]
    Curious if Adam will pay you a percentage of his royalties since he essentially cut and pasted your article on another site? His article posted 10 minutes after the first comment was made on your article.
    Oct 10, 2012. 03:34 PM | 4 Likes Like |Link to Comment
  • Amarin NCE Decision Delayed Again: What The 8-K Really Tells Us  [View article]
    You make good points regarding the language of the 8K. Amarin making reference to the three paths to marketing leads me to believe an offer has been submitted. My thoughts are that the offer is below Joe Z's expectations and does not take into account Marine and Reduce-It trials. Joe wants the offerer(s) to pay a price based on the true value of the drug as well as what the drug will be worth. I am convinced Amarin will go it alone utilizing an outside sales force while waiting for the pending trial results and the offer that takes those into account. I am prepared to sit tight while Amarin builds value over the next year.
    Oct 10, 2012. 02:24 PM | 1 Like Like |Link to Comment